Biweekly administration of docetaxel and carboplatin for advanced or recurrent endometrial and ovarian carcinomas.
CONCLUSION: The present results showed that biweekly administration of docetaxel and carboplatin for advanced and recurrent endometrial and ovarian carcinomas results in acceptable side effects, response rate, and PFS.
PMID: 29894072 [PubMed - in process]
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
More News: Cancer & Oncology | Carcinoma | Docetaxel | Endometrial Cancer | OBGYN | Ovarian Cancer | Ovaries | Study | Taxotere